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Comparison of low molecular weight heparin to standard heparin in
hemodialysis/hemofiltration. Low molecular weight (LMW) heparin has
been compared to standard unfractionated (UF) heparin in hemodialy-
sis/hemofiltration in a 12 month, randomized study. Seventy patients
with end-stage chronic renal failure starting dialysis treatment were
randomly assigned to one of two groups treated with either LMW or UF
heparin. The LMW and UF heparin doses used produced similar
plasma anti-FXa levels, and comparable antithrombotic effectiveness
was observed in the two groups as reflected in similar incidences of
thrombus formation in the extracorporeal circulation: 1.59% and 1.33%
for LMW and UF heparin, respectively. No bleeding complications
were seen with either heparin, but significantly (P < 0.05) fewer
erythryocyte concentrates were needed in the LMW heparin patients.
Mean factor VIII activities had risen significantly (P < 0.001) after 12
months in the UF heparin group, whereas they were unchanged in the
LMW heparin group. A significant (P < 0.05) increase in plasma
triglycerides was observed in the UF heparin group which was attrib-
utable to six (18.8%) of the patients in this group. Triglyceride concen-
trations remained relatively constant in the LMW heparin group.
Post-heparin lipolytic activity, and in particular hepatic lipase activity,
was not stimulated to the same extent in the LMW heparin-treated
patients as compared to the UF heparin group. We conclude that LMW
heparin is a suitable alternative to standard UF heparin for anticoagula-
tion in hemodialysis/hemofiltration therapy. It may offer potential
advantages with regard to a lower requirement for erythrocyte concen-
trates and less derangement of certain metabolic parameters, such as
factor VIII, triglycerides and plasma lipase activity.
The introduction of heparin as an anticoagulant was a major
step in the development of hemodialysis for the treatment of
acute and chronic renal failure. Although heparin has over the
years proven to be a reliable anticoagulant there are still several
undesirable side effects which can lead to complications. In
particular, due to improvements in dialysis techniques a larger
number of patients who are at bleeding risk are now being
treated by dialysis. Furthermore, since hemodialysis patients
require long-term treatment which is often spread over several
years, repeated heparin therapy may augment chronic occult
blood loss [11, thus leading to a further deterioration of the renal
anemia in these patients and an increased need for erythrocyte
concentrates. Heparin is also known to adversely affect both
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the coagulation and immune systems as well as the plasma
lipoproteins [2—6]. Such effects may be of clinical importance in
the long-term treatment of dialysis patients.
Several recent publications [7—101 have suggested that a low
molecular weight heparin fraction (LMW heparin) may have
potential therapeutic advantages over normal unfractionated
heparin (UF heparin). In animal experiments LMW heparin was
found to have similar antithrombotic activity to standard hepa-
nfl while at the same time displaying reduced hemorrhage
[11—13]. The lower bleeding losses with LMW heparin were
attributed to the fact that this derivative does not impair
thrombocyte function to the same extent as standard UF
heparin [14, 151. Other studies have shown that LMW heparin
does not stimulate total plasma lipase activity to the same
extent as UF heparin [16]. In a six month investigation on
patients being treated by hemodialysis and hemofiltration, low
molecular weight heparin was found to be a suitable alternative
to unfractionated heparin for anticoagulant therapy [10, 17]. In
contrast to standard heparin, a significant correlation was
observed between antithrombotic activity and factor Xa-activ-
ity in plasma when using LMW heparin.
In this article we describe the results of a randomized,
long-term study comparing LMW heparin with UF heparin for
anticoagulant therapy in hemodialysis and hemofiltration pa-
tients. All patients were new to dialysis/filtration and were
randomly assigned to either the LMW or UF heparin group.
Particular attention was paid to antithrombotic activity, side
effects and long-term changes in the coagulation, lipid and
lipoprotein parameters of the two groups.
Methods
Patients and study design
Seventy patients (40 male, 30 female) requiring dialysis for
end-stage renal failure were recruited into this study. None had
been previously treated by dialysis and they had not been on
heparin therapy for a period of at least three months prior to the
start of the investigation. Patients with known bleeding disor-
ders or who required additional treatment with oral anticoagu-
lants or anti-platelet drugs were excluded from the study.
The patients had originally been referred to one of five
different nephrology departments. After randomization into two
groups, treatment was performed at each of the five centers.
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Table 1. Clinical characteristics of the two study groups
Characteristic
Treatment group
LMW (N = 35) UF (N = 35)
Age yr (mean SD) 54.0 15.2 51.6 17.9
Sex M/F 21/14 19/16
Hemodialysis 29 29
Hemofiltration 6 6
Reasons for renal failure
Glomerulonephritis II 9
Diabetic nephropathy 5 8
Interstitial nephritis 5 5
Pyelonephritis 4 6
Cystic kidney disease 5 3
Nephrosclerosis 2 3
Amyloidosis 1
M Fabry's syndrome/ 1/1 0
Nephronophthisis
Reasons lost for follow-up 5 3
Death by myocardial 2 1
infarction
Death because of 0 1
uremia
Renal transplantation 1 0
Changed to peritoneal 1 0
dialysis
Change of the dialysis 1
center
Patients remained at the center to which they had originally
been referred for the complete study period. The two groups
were randomly distributed between the five centers. Group 1(21
male, 14 female) was administered LMW heparin as anticoagu-
lant while group 11(19 male, 16 female) received a commercial
unfractionated heparin. Characteristics of the patients from
both groups were similar (Table 1), indicating satisfactory
random assignment. A total of eight patients were lost to
follow-up, five in group I (LMW heparin) and three in group II
(UF heparin) (Table I).
The LMW and UF heparin doses employed were based on
the results of previous investigations [10, 171. The mean initial
doses required for both LMW (anti-FXa units/kg) and UF
heparin (lU/kg) are given in Figure 1, together with their
respective infusion rates (dose/hr). In individual cases if clotting
occurred in the extracorporal system, or if anti-FXa activities
were either below 0.4 U/mI or above 1.2 U/ml, a corresponding
dose adjustment was made at the next dialysis procedure.
Twenty-nine patients from each group were treated by hemo-
dialysis and the remaining six by hemofiltration. During the
study the particular dialysis or filtration procedure used for
each patient was not altered; the same type of dialyzer or
hemofilter was always used in the same patient. All dialyzers
and hemofilters were made from cuprophane membranes. Treat-
ment usually lasted between four and a half to five hours at
blood flow rates ranging from 150 to 400 mI/mm. When neces-
sary erythrocyte infusions were given if the hemoglobin values
dropped below 6.5 g/dl. Blood samples were drawn after an
overnight fast prior to the start of each dialysis/filtration proce-
dure and where stated after the first two hours of treatment.
Sampling was performed on the first day of treatment and after
a further six and twelve months.
The heparin preparations used in the study were as follows:
LMW heparin. Fragmin' (KB Vitrum, Stockholm, Sweden);
average molecular weight 5000 to 6000 daltons; anti-FXa-
activity (chromogenic substrate S-2222) 160 U/mg; aPTT 40
lU/mg; anti-FXa-PTT ratio = 4.
UF heparin. LiqueminR (Hoffman-LaRoche, Basel, Switzer-
land); average molecular weight 12000 to 15000 daltons, anti-
FXa-activity (chromogenic substrate S-2222) 175 U/mg; aPTT
165 iU/mg; anti-FXa-aPTT ratio = 1.
Laboratory parameters
Plasma heparin activity was monitored as anti-FXa-activity
[18] using a chromogenic substrate (S-2222, KB Vitrum, Mu-
nich, FRG). The following coagulation parameters were deter-
mined with commerically available assay systems: activated
partial thromboplastin time, aPTT (pathromtin, Behring,
Marburg, FRG); thromboplastin time according to Quick (Ca-
thromboplastin, Behring); fibrinogen according to Clauss (Im-
muno, Heidelberg, FRG); fibrin monomers [19]; factor-Vu
activity (clotting assay, Behring); antithrombin-III (chromo-
genic substrate S-2238, KB Vitrum); plasminogen and a-2-anti-
plasmin [20]. Total plasma post-heparin lipase (PHLA) activity
was measured using ('4C)-labeled triolin as substrate [21, 221
prepared essentially as described [21], with the exception that
phosphatidyl choline was used instead of Triton-X to stabilize
the emulsion. Substrate was prepared daily by sonification of
the following: 2.5 Ci glycerol-tn (1-'4C) oleate (Amersham);
100mg triolin; 6 mg phosphatidyl choline; 200 mg fatty acid-free
bovine albumin in 12 ml, 0.2 M Tris-HCI, pH 8.6; 0.15 M NaC1.
Lipase assays were routinely carried out by incubation of 25 d
plasma with 25 p1 0.91 M Tris-HCI, pH 8.6, 0.2 M NaCI
containing 30 lU/mI Na-hepanin at 27°C for 10 minutes, fol-
lowed by addition of 450 pi substrate emulsion and a further
incubation for 60 minutes. The reaction was stopped by adding
200 pJ of the incubation mixture to 3.25 ml of methanol:
chloroform:heptane (141:125:100), and free fatty acids were
extracted with 0.1 M K2C03 (1.05 ml). After mixing on a vortex
mixer for one minute and centrifugation for 15 minutes, I ml of
E
cc
C
N=35 35 35 35 33 32 32 30 32 30
UF
Initialdose: 60.4±24.4 65.4±27.6 62.6±26.2 63.3±27.7 58.3±26.3
Dose/hr: 17.4±5.9 19.0±7.4 16.6±5.9 17.3±6.6 16.6±6.7
LMW
Initialdose: 33.3± 12.7 31.8±9.1 34.7±12.9 34.8±11.1 36.8±17.3
Dose/hr: 12.0±4.0 12.0±4.5 12.7±5.8 12.2±4.2 12.2±5.0
Heparin, anti-FXa-activity
Fig. 1. Mean anti-FXa activities (± SD) determined 2 hours after the
start of dialysis or filtration in the 2 groups during the study period. The
mean doses of UF heparin and LMW heparin employed are also given
as lU/kg, and anti-FXa U/kg, respectively.
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the aqueous phase was transferred to a scintillation vial and
after neutralization with glacial acetic acid, and addition of 10
ml instagel scintillation fluid, radioactivity was measured in a
scintillation counter. PHLA was expressed as smol free fatty
acids (FFA) released ml hr. Hepatic triglyceride lipase
activity (HTGL) was determined in the presence of 1 M NaCl to
inhibit lipoprotein lipase (LPL). The latter was calculated from
the difference between total PLHA and HTGL. Total serum
cholesterol (CHOD-PAP, Boehringer, FRG) and total serum
triglycerides (Wako Chemicals, Neuss, FRO) were determined
with commercially available enzymatic test kits. The individual
lipoprotein fractions were measured by quantitative lipoprotein
electroresis (Lipidophor, Immuno, Heidelberg, FRG). Other
parameters were measured by standard techniques subject to
stringent quality control in the Department of Clinical Chemis-
try, University of Goettingen.
Statistical analyses
Statistical analyses were performed using the statistical anal-
ysis system. Normal distribution of the variables were first
verified by means of the Shapiro-Wilk-statistic. Significant
differences between the LMW heparin and UF heparin groups
were determined by the unpaired Student's t-test. Significant
differences within each group were tested using the paired
Student's t-test. Differences in frequencies between the two
groups were checked with the chi square test or, if there were
only a small number of parameters in the two by two table,
Fisher's exact test was used.
Results
Patients
Of the 70 patients who were enrolled into this study, a total of
62 completed 12 months of treatment by hemodialysis or
hemofiltration using either LMW heparin (N = 30, group I) or
UF heparin (N = 32, group II) as anticoagulant (Table 1). None
of the losses to follow up could be attributed to either of the two
heparins used in this study (Table 1).
Anti-FXa-levels
As would be expected from the study design, no significant
differences were observed in the plasma anti-FXa concentra-
tions either between groups I and II or within each group during
the course of 12 months of treatment (Fig. 1). Mean values
ranged from 0.59 to 0.74 anti-FXa U/ml. In order to obtain
similar plasma anti-FXa-levels, the total LMW heparin dose
(bolus + infusion) was approximately 2/3 that of the UF heparin
dose in terms of anti-FXa units.
Thrombosis in the extracorporeal system
From a total of 10,242 hemodialysis/hemofiltration proce-
dures, 149 cases of thrombus formation in the extracorporeal
system were recorded, an incidence rate of 1.46%. No signifi-
cant difference was observed between the two groups (Table 2),
with an incidence rate of 1.33% (69 of 5187) in the UF heparin
group and 1.59% (80 of 5045) in the LMW heparin group. In
65.9% of the cases in which thrombus formation occurred,
plasma anti-FXa concentrations were below 0.5 U/mI.
Table 2. Frequency of thrombosis and erythrocyte concentrate
requirement in the two study groups
LMW heparin UP heparin
Thrombosis of the extracorporal 80 69
circulation
Number of dialysis/filtrations 5045 5197
Frequency% 1.59 1.33
Patients requiring erythrocyte 19 16
concentrates
Number of dialysis/filtrations 2808 2288
Number of erythrocyte 76 88
concentrates
Frequency% 2.71 3.85a
a P < 0.05.
Erythrocyie transfusions
No bleeding complications were observed with either of the
two heparins during the 12 month study. Erythrocyte concen-
trates were administered during the course of this study if
hemoglobin levels fell below 6.5 gldl. A total of 19 patients in
the LMW heparin group and 16 patients in the UF heparin
group required such transfusions. The number of transfusions
performed amounted to 76 in the former and 88 in the latter
group. Dialysis/filtration procedures (2808) were performed on
the 19 patients requiring transfusions in the LMW heparin
group, corresponding to one erythrocyte concentrate for every
37 dialysis/filtration procedure (2.7 1%). In the UF-heparin
group, 2288 dialysis/filtration procedures were performed on
the 16 patients, amounting to a frequency of one concentrate for
every 26 dialysis/filtration treatment (3.85%). The difference
between the two groups achieved statistical significance (P <
0.05, Table 2).
Coagulation parameters
All coagulation parameters were measured both before and
after the start of dialysis/filtration. No changes in the pre-
dialysis factor-Vill activities were observed in the LMW hepa-
rin group during the 12-month study period. In contrast, a
significant rise in factor-VIlI activity occurred in the UF
heparin group during the year (P <0.05 after six months, P <
0.001 after twelve months). At the end of twelve months there
was a significant difference between the mean factor-Vill
activities in the two groups (P < 0.001, Table 3). Plasma
factor-Vill activities rose to the same extent in each group
during each dialysis or filtration procedure (Table 3).
A significant decrease was observed in pre-dialysis levels of
fibrin-monomers after both six (P <0.01) and twelve months (P
< 0.01) of treatment in the LMW heparin group whereas no
changes were observed in the UF heparin group. The differences
in fibrin-monomer concentrations between the two groups after
six and twelve months of treatment also reached statistical
significance (P < 0.05). Fibrin-monomer levels did not, how-
ever, increase during dialysis in either of the two groups.
Although pre-dialysis aPTT-values had decreased in both
groups after twelve months (P < 0.05), there was no significant
difference between the two groups. No differences were ob-
served in pre-dialysis thrombin times either during the course of
the study or between the two groups. Both aPTT and thrombin
times increased significantly (P < 0.001) during dialysis in the
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Table 3. Long-term changes in various blood coagulation parameters in the two groups dunng the study period (mcan SD)
Months
LMW heparin UF heparin
0 6 12 0 6 12
Factor VIII %
AD 241 126 247 l09 220 81 235 l02 268 l07 306 112•
2hr 269 I39 285 150g 251 90S 299 ll4 326 l2l 347 iio
Fibrin monomers
AD 0.60 0.57 0.35 028b,d 0.29 O.26" 0.47 0.45 0.48 O.4'7 0.42 0.52"
2 hr 0.67 0.73 0.29 0.28" 0.35 0.36 0.50 0.43 0,46 0.56" 0.36 0.45
aPTT sec
AD 43.0 6.6 43.6 9.0 40.3 4.2a 42.7 6.8 40.7 6.4 40.3 6.7a
2 hr 55.8 138e,h 539 l3.3 47.8 95e,h 136.4 805e,h 174.6 96.9e 135.9 809,h
Thrombin time sec
AD 20.4 2.4 19.5 2.2 19.9 2.0 19.6 2.2 19.3 2.0 19.9 2.0
2 h 27.6 7.3" 27.5 9.8" 27.3 9.2 215.9 1265e.h 243.9 ll0.l" 208.0 121,2e,h
AT III %
AD 114 17 98 19C 97 15c Ill 22 101 14b ioo
2 hr 114 18 98 24 101 17 115 17 103 15 103 19
Fibrinogen mg/dl
AD 374 80 327 8 314 64b 345 68 317 79 307 70b
2 hr 391 88 338 85 343 67 359 71 339 79 332
Abbreviations are: AD, pre-dialysis value; 2 hr, value 2 hours after start of dialysis.
a p < 0.05, mean values within the same study group (e.g. between 0 and 6 or 12 month)b P < 0.01, mean values within the same study group (e.g. between 0 and 6 or 12 month)
P < 0.001, mean values within the same study group (e.g. between 0 and 6 or 12 month)d P < 0.05, mean values from the two different study groups at the same point in time
P < 0.001, mean values from the two different study groups at the same point in time
P < 0.05, AD and 2 hr values
P < 0.01, AD and 2 hr valuesh P <0.001, AD and 2 hr values
two groups; the greatest increases were observed in the UF
heparin group. Similarly, the greatest reduction in thromboplas-
tin time (according to Quick) during dialysis or filtration was
seen in the UF heparin group.
Plasminogen and a-2-antiplasmin activities did not alter dur-
ing the twelve months and no differences were observed be-
tween the two groups.
Antithrombin III (AT III) activities had decreased slightly but
significantly in both groups after six and twelve months of
treatment. No significant changes were observed during dialy-
sis. Fibrinogen levels showed a small but significant reduction
in both groups during the study but there was no significant
difference between the two groups themselves. Dialysis was
associated with a slight increase in fibrinogen concentration in
both groups.
Plasma lipoproteins and lipase activities
A significant increase was observed in the mean plasma
triglyceride concentrations of the UF heparin treated patients
during the course of this study, whereas in the LMW heparin
group plasma triglyceride levels remained constant (Table 4).
This increase in the UF heparin group was largely attributable
to six patients who developed marked hypertriglyceridemia
(>450 mgldl) during this study. Thus the mean plasma triglyc-
eride concentration of these six patients was 251 Ill mgldl at
the start of therapy and 619 209 mgldl after twelve months of
treatment. None of the UF heparin patients had triglyceride
levels greater than 450 mgldl at the start of treatment. In the
case of the LMW heparin group, two patients had triglyceride
concentrations greater than 450 mgldl at the start of treatment,
and only one patient remained at such a level after twelve
months of treatment. The difference in the incidence of this
marked hypertriglyceridemia in the two groups after twelve
months was significant (P < 0.05). Quantification of the indi-
vidual lipoprotein fractions revealed that the increase in triglyc-
erides in the UF heparin treated group was associated with a
significant increase in pre-3-lipoproteins (VLDL) cholesterol,
whereas 3-lp (LDL) and a-Lp (HDL) cholesterol levels re-
mained unchanged.
Post-heparin lipolytic activities (PHLA) were measured two
hours after the start of dialysis or filtration. PHLA was signif-
icantly higher in the UF heparin group as compared to the
LMW heparin group (Table 4). The increase in total PHLA was
primarily due to a rise in the hepatic lipase activity in the UF
heparin group. There were, however, no changes in the extent
of this PHLA increase during the course of treatment in either
group.
Discussion
The LMW and UF heparin doses employed for anticoagula-
tion therapy in this randomized long-term study on hemodialy-
sis and hemofiltration patients led to similar plasma anti-FXa
levels in the two groups. Both heparin species had comparable
antithrombotic activity at the doses used, as illustrated by the
similar incidences of thrombus formation in the extracorporeal
system, 1.59% and 1.33% for LMW and UF heparin, respec-
tively. Furthermore, the majority of such cases (65.9% of
thrombus formation) were associated with plasma anti-FXa
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Table 4. Long-term changes in lipids, lipoproteins, plasma lipase, crcatinine, urea and hemoglobin (mean SD)
Months
LMW heparin UF heparin
0 6 120 6 12
Triglycerides mg/dl
Cholesterol mg/dl
/3-Cholesterol mg/di
pre-/3-Cholesterol
mg/di
a-Cholesterol mg/d!
HTGL p.ing! FFA/
mi/hr
LPL ,rsmglFFA/m!/
hr
Creatinine mg/d!
Urea mg/di
Hemoglobin g/dI
228 123
218 63
155 56
34 27
35 IS
2.6 I.8
1.3 0.71
10.6 3.3
152 81
9.0 1.5
245 137
221 63
146 51
33 22
37 16
10.5 3.0
123 51
8.5 1.2
228
229
155
40
35
3.4
1.9
10.7
127
8.0
122"
70
57
32
15
2.O
1.5
2.4
61
1.2"
188
212
145
28
39
5.8
2.2
9.7
145
8.7
106
50
43
20
15
3.2
2.2"
3.8
71
1.3
252 177"
212 48
132 38
40 31"
40 18
—
10.8 3.0
128 58
8.4 1.3
256
217
142
38
41
6.4
2.4
11.1
131
8.0
18o""
SI
37
33"
17
2.5
1.5
3.0
56
1.3"
Superscripts are listed in Table 3.
levels below 0.5 U/mI. This agrees well with the results of Lane
et al [23] who showed that in dialysis patients, llbrinopeptide-A
and thrombus formation is effectively suppressed at plasma
anti-FXa levels above 0.5 U/mI. These data confirm our earlier
observations [10, 171 that LMW heparin is an effective antico-
agulant in hemodialysis or hemofiltration therapy despite its
minimal effect on aPTT and thrombin time. Furthermore,
antithrombotic effectiveness in such patients is correlated to
plasma anti-FXa levels. However it is uncertain whether the
antithrombotic effectiveness can be attributed to the anti-FXa
effects of low molecular weight heparin alone or whether it is
due to other effects of the low molecular weight heparin [24,
251.
Although no bleeding complications were observed with
either heparin during the entire study, it is of interest that the
LMW heparin group required significantly fewer erythrocyte
concentrates than the UF treated patients. The indication for
transfusion in both groups was a hemoglobin level below 6.5
gldl. In the UF heparin group the incidence for transfusion was
one concentrate for every 26 dialysis or ultrafiltration proce-
dures as opposed to one in 37 for the LMW heparin group.
Similar results have been reported from another non-rando-
mized short-term investigation [26]. The reasons for this in-
creased time interval between transfusions in the LMW heparin
group are not known. It may be speculated that occult blood
losses are lower in this group since LMW heparin does not
greatly affect thrombocyte function [27, 28]. In particular it has
been demonstrated by Borm et al [29] that in contrast to UF
heparin, LMW heparin does not cause a reduction in thromb-
ocyte adhesion during dialysis. Irrespective of the exact mech-
anism by which LMW heparin reduces the erythrocyte concen-
trate requirement of dialysis patients, the clinical and economic
benefits are evident in terms of a lowering of transfusion
transmitted diseases (hepatitis, HTLV-1l1).
Although AT III concentrations fell slightly during the course
of this study in both groups, there was no significant difference
between the two. Similar heparin-induced decreases in AT III
have been reported in the literature [25], but this does not
appear to be of any great clinical importance.
Patients with chronic renal insufficiency often have massively
elevated factor-Vill activities. During this present study factor-
VIII activity increased significantly in the UF group in partic-
ular during the latter six months. In contrast, there were no
corresponding changes in the LMW group. In a previous study
on patients who had already been in a dialysis program for some
time, it was found that on changing to LMW heparin, factor-
VIII levels decreased over a treatment period of six months
[10]. The reasons for the elevated factor-VIlI activities in
dialysis patients are unclear although it has been suggested that
these may result from damage to the endothelium. If this is so,
it may be due to the fact that LMW heparin has less effect on
the vascular endothelium than does UF heparin [30].
Hypertriglyceridemia is often associated with terminal renal
insufficiency and this is not corrected by dialysis but in fact may
be accentuated [31, 32]. In this present investigation we ob-
served a significant rise in triglyceride levels, already evident
after six months, in the UF heparin treated patients. This rise
could be attributed to six (18.8%) of the 32 patients in this
group. Despite some fluctuations, no significant change in
triglycerides was observed in the LMW heparin patients. Both
increased synthesis and impaired catabolism [33] have been
implicated in the hypertriglyceridemia of uremic patients on
dialysis. The reasons for the impaired catabolism are not known
although it has been suggested that this may be due to inhibition
of lipases through an uremic factor [34] and/or a diminuition in
lipolytic activity due to the repeated heparin treatment [31, 35].
We have been able to demonstrate that in normal persons
heparin infusions similar to those used in dialysis patients with
LMW heparin cause a significantly lower increase in HTGL and
LPL activities than does UF heparin [36]. After four hours of
continuous heparin infusion in normal persons, further stimu-
lation of lipolytic activity was not possible in those persons who
had received a UF heparin infusion in comparison to a LMW
heparin infusion. In this present study, measurement of lipase
levels two hours after the start of dialysis revealed that the
LMW heparin patients also had reduced lipase activities com-
pared to the UF heparin groups.
Since lipoprotein lipase is rapidly released from the endothe-
hum on injection of heparin, these two hour values might not
necessarily reflect the initial release of lipase activity at the start
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of hemodialysis. However, in a subsequent study [361 we have
been able to confirm that LMW heparin does indeed cause a
significantly lower release of lipase activity compared to UF
heparin when measured 10 minutes after injection of the heparin
bolus.
No correlations were observed between PHLA activity and
the degree of hypertriglyceridemia in the individual patients. It
cannot, therefore, be ascertained from the present data as to
whether the hypertriglyceridemia in the six patients from the
UF heparin group is due to a heparin-induced lipase deficiency.
It is also conceivable that heparin may inhibit the binding and
uptake of triglyceride rich lipoprotein remnants by receptors in
the liver. If this were the case then UF heparin would have to
be a more potent inhibitor than LMW heparin. We are currently
investigating this hypothesis. It would also be of interest to
determine whether in severely hypertriglyceridemic dialysis
patients who have previously been on UF heparin therapy, a
reduction in triglyceride levels can be achieved by changing to
LMW heparin. Such studies are at present in progress.
Patients on dialysis have a high rate of cardiovascular com-
plications [37, 38]. There is still controversy as to whether the
accelerated atherosclerosis of dialysis is due to dialysis itself, or
simply reflects a high prevalence of major risk factors in such
patients. Several factors have been implicated in the atheroscle-
rosis of dialysis patients including endothelial cell damage,
impaired platelet function, elevated factor-Vill levels and im-
paired clearance of triglyceride-rich lipoprotein remnants [391.
In this respect LMW heparin would appear to offer certain
advantages over UF heparin since the former leads to an
improvement in both factor-VIII levels and triglyceride concen-
trations in dialysis patients. Further long-term studies will,
however, be necessary in order to determine whether the use of
LMW heparin can indeed lower the high rate of atherosclerosis
in dialysis therapy.
A further potential advantage of the reduced lipolytic activity
due to LMW heparin may lie in its influence on the immune
system since it is known that in particular in dialysis patients,
free fatty acids increase plasma cell toxicity [4]. Since LMW
heparin does not induce such high free fatty acid concentrations
as UF heparin [16], a smaller toxic effect on plasma cells might
be expected with the former. This may be of clinical importance
when one considers that dialysis patients have a high infection
rate.
When using LMW heparin it is important to realise that
conventional coagulation assays cannot be used to screen for
anticoagulatory activity and plasma anti-FXa activity must be
measured instead. There is also no international standardization
of LMW heparins and there may therefore be considerable
differences in the properties of the different products presently
available. The results obtained with the particular LMW hepa-
rin used in this study may not be comparable to those that
would be obtained using other LMW heparins. It should also be
noted that the half-life of LMW heparin is about twice that of
UF heparin.
The major results of this randomized long-term study may be
briefly summarized as follows. (I) LMW heparin is an effective
alternative to standard UF heparin for anticoagulant therapy in
hemodialysis/hemofiltration. (2) The use of LMW heparin may
lead to a lower requirement for erythrocyte concentrates during
hemodialysis/hemofiltration therapy. (3) LMW heparin does not
affect plasma factor-Vu! levels and does not exacerbate uremic
hypertriglyceridemia.
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